SEARCH

SEARCH BY CITATION

References

  • Backert S., Gelos M., Kobalz U., Hanski M. L., Bohm C., Mann B., Lovin N., Gratchev A., Mansmann U., Moyer M. P., Riecken E. O., Hanski C. (1999) Differential gene expression in colon carcinoma cells and tissues detected with a cDNA array. Int. J. Cancer 82, 868874.DOI: 10.1002/(sici)1097-0215(19990909)82:6<868::aid-ijc16>3.3.co;2-n
  • Bernheimer H., Birkmayer W., Hornykiewicz O., Jellinger K., Seitelberger F. (1973) Brain dopamine and the syndrome of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J. Neurol. Sci. 20, 415455.
  • Bessler H., Djaldetti R., Salman H., Bergman M., Djaldetti M. (1999) IL-1β, IL-2, IL-6 and TNF-α production by peripheral blood mononuclear cells from patients with Parkinson's disease. Biomed. Pharmacother. 53, 141145.DOI: 10.1016/s0753-3322(99)80079-1
  • Bowie A. & O'Neill L. A. (2000) Oxidative stress and nuclear factor-kappaB activation: a reassessment of the evidence in the light of recent discoveries. Biochem. Pharmacol. 59, 1323.DOI: 10.1016/s0006-2952(99)00296-8
  • Carboni S., Melis F., Pani L., Hadjiconstantinou M., Rossetti Z. L. (1990) The noncompetitive NMDA-receptor antagonist MK-801 prevents the massive release of glutamate and aspartate from rat striatum induced by 1-methyl-4-phenypyridinium (MPP+). Neurosci. Lett. 117, 129133.
  • Debouck C. & Goodfellow P. N. (1999) DNA microarrays in drug discovery and development. Nat. Genet. Suppl. 21, 4850.
  • DeRisi J., Penland L., Brown P. O., Bittner M. L., Meltzer P. S., Ray M., Chen Y., Su Y. A., Trent J. M. (1996) Use of a cDNA microarray to analyze gene expression patterns in human cancer. Nat. Genet. 14, 457460.
  • Dey A., Jones J. E., Nebert D. W. (1999) Tissue- and cell type-specific expression of cytochrome P450 1A1 and cytochrome P450 1A2 mRNA in the mouse localized in situ hybridization. Biochem. Pharmacol. 58, 525537.DOI: 10.1016/s0006-2952(99)00110-0
  • Garthwaite J., Garthwaite G., Palmer R. M., Moncada S. (1989) NMDA receptor activation induces nitric-oxide synthesis from arginine in rat-brain slices. Eur. J. Pharmacol. 172, 413416.
  • Gash D. M., Zhang Z., Gerhardt G. (1998) Neuroprotective and neurorestorative properties of GDNF. Ann. Neurol. Suppl. 44, 121125.
  • Gassen M., Glinka Y., Pinchasi B., Youdim M. B. H. (1996) Apomorphine is highly potent free radical scavenger in rat mitochondrial fraction. Eur. J. Pharmacol. 308, 219225.DOI: 10.1016/0014-2999(96)00291-9
  • Gassen M., Gross A., Youdim M. B. H. (1998) Apomorphine enantiomers protect cultured pheochromocytoma (PC12) cells from oxidative stress induced by H2O2 and 6-hydroxydopamine. Mov. Disord. 13, 242248.
  • Gerlach M. & Riederer P. (1996) Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man. J. Neural. Transm. 103, 9871041.
  • Gray N. S., Wodicka L., Thunnissen A. M., Norman T. C., Kwon S., Espinoza F. H., Morgan D. O., Barnes G., LeClerc S., Meijer L., Kim S. H., Lockhart D. J., Schultz P. G. (1998) Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science 281, 533538.
  • Grünblatt E., Mandel S., Berkuzki T., Youdim M. B. H. (1999) Apomorphine protects against MPTP-induced neurotoxicity in mice. Mov. Disord. 14, 612618.
  • Hadjiconstantinou M., Fitkin J. G., Dalia A., Neff N. H. (1991) Epidermal growth factor enhances striatal dopaminergic parameters in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mouse. J. Neurochem. 57, 479482.
  • Heller R. A., Schena M., Chai A., Shalon D., Bedilion T., Gilmore J., Woolley D. E., Davis R. W. (1997) Discovery and analysis of inflammatory disease-related genes using cDNA microarrays. Proc. Natl Acad. Sci. USA 94, 21502155.DOI: 10.1073/pnas.94.6.2150
  • Hunot S., Bernard V., Faucheux B., Boissiere F., Leguern E., Brana C., Gautris P. P., Guerin J., Bloch B., Agid Y., Hirsch E. C. (1996) Glial cell line-derived neurotrophic factor (GDNF) gene expression in the human brain: a post mortem in situ hybridization study with special reference to Parkinson's disease. J. Neural. Transm. 103, 10431052.
  • Hunot S., Brugg B., Ricard D., Michel P. P., Muriel M. P., Ruberg M., Faucheux B. A., Agid Y., Hirsch E. C. (1997) Nuclear translocation of NF-κB is increased in dopaminergic neurons of patients with Parkinson's disease. Proc. Natl Acad. Sci. USA 94, 75317536.DOI: 10.1073/pnas.94.14.7531
  • Ishii T., Yanagawa T., Yuki K., Kawane T., Yoshida H., Bannai S. (1997) Low molecular levels of hydrogen peroxide and proteasome inhibitors induce the 60-kDa A170 stress protein in murine peritoneal macrophages. Biochem. Biophys. Res. Commun. 232, 3337.DOI: 10.1006/bbrc.1997.6221
  • Jellinger K., Paulus W., Grundke-Iqbal I., Riederer P., Youdim M. B. H. (1990) Brain Iron and ferritin in Parkinson's and Alzheimer's disease. J. Neural. Transm. 2, 327340.
  • Lee C. K., Klopp R. G., Weindruch R., Prolla T. A. (1999) Gene expression profile of aging and its retardation by caloric restriction. Science 285, 13901393.DOI: 10.1126/science.285.5432.1390
  • Li S. H., Hosseini S. H., Gutekunst C. A., Hersch S. M., Ferrante R. J., Li X. J. (1998) A human HAP1 homologue. Cloning, expression, and interaction with huntingtin. J. Biol. Chem. 273, 1922019227 .DOI: 10.1074/jbc.273.30.19220
  • Liberatore G. T., Jackson-Lewis V., Vukosavic S., Mandir A. S., Vila M., McAuliffe W. G., Dawson V. L., Dawson T. M., Przedborski S. (1999) Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Nat. Med. 5, 14031409.DOI: 10.1038/70978
  • Lin L. F., Doherty D. H., Lile J. D., Bektesh S., Collins F. (1993) GDND: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 260, 11301132.
  • Lin M., Rippe R. A., Niemela O., Brittenham G., Tsukamoto H. (1997) Role of iron in NFkB activation and cytokines gene expression by rat hepatic macrophages. Am. J. Physiol. 272, G1355G1364.
  • Liu J. H., Wei S., Burnette P. K., Gamero A. M., Hutton M., Djeu J. Y. (1999) Functional association of TGF-β receptor II with cyclin B. Oncogene 18, 269275.
  • Marton M. J., DeRisi J. L., Bennett H. A., Iyer V. R., Meyer M. R., Roberts C. J., Stoughton R., Burchard J., Slade D., Dai H., Bassett D. E. Jr, Hartwell L. H., Brown P. O., Friend S. H. (1998) Drug target validation and identification of secondary drug target effects using DNA microarrays. Nat. Med. 4, 12931301.DOI: 10.1038/3282
  • Mogi M., Harada M., Narabayashi H., Inagaki H., Minami M., Nagatsu T. (1996) Interleukin (IL)-1β, IL-2, IL-4, IL-6 and transforming growth factor-α levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonian and Parkinson's disease. Neurosci. Lett. 211, 1316.DOI: 10.1016/0304-3940(96)12706-3
  • Mogi M., Togari A., Ogawa M., Ikeguchi K., Shizuma N., Fan D., Nakano I., Nagatsu T. (1998) Effects of repeated systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to mice on interleukin-1β and nerve growth factor in the striatum. Neurosci. Lett. 250, 2528.DOI: 10.1016/s0304-3940(98)00427-3
  • Mori S., Fujitake J., Kuno S., Sano Y. (1988) Immunohistochemical evaluation of the neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on dopaminergic nigrostriatal neurons of young adult mice using dopamine and tyrosine hydroxylase antibodies. Neurosci. Lett. 90, 5762.
  • Movsesyan V., Whalin M., Shibutani M., Katagiri Y., Broude E., Guroff G. (1996) Down-regulation of cyclin F levels during nerve growth factor-induced differentiation of PC12 cells. Exp. Cell Res. 227, 203207.DOI: 10.1006/excr.1996.0268
  • Olanow C. W. (1996) Neurodegeneration and Neuroprotection in Parkinson's Disease. N.Y. Acad. Press, New York.
  • Philpott C. C., Rashford J., Yamaguchi-Iwai Y., Rouault T. A., Dancis A., Klausner R. D. (1998) Cell-cycle arrest and inhibition of G1 cyclin translation by iron in AFT1–1up yeast. EMBO J. 17, 50265036.DOI: 10.1093/emboj/17.17.5026
  • Polidori M. C., Mecocci P., Browne S. E., Senin U., Beal M. F. (1999) Oxidative damage to mitochondrial DNA in Huntington's disease parietal cortex. Neurosci. Lett. 272, 5356.DOI: 10.1016/s0304-3940(99)00455-3
  • Riedl A. G., Watts P. M., Jenner P., Marsden C. D. (1998) P450 enzymes and Parkinson's disease: the story so far. Mov. Disord. 13, 212220.
  • Santos B. C., Chevaile A., Kojima R., Gullans S. R. (1998) Characterization of the Hsp110/SSE gene family response to hyperosmolarity and other stresses. Am. J. Physiol. 274, F1054F1061.
  • Schreck R., Rieber P., Baeuerle P. A. (1991) Reactive oxygen intermediates as apparently widely used messengers in the reactivation of the NF-kappa B transcription factor and HIV-1. EMBO J. 10, 22472258.
  • Swift S., Blackburn C., Morahan G., Ashworth A. (1998) Structure and chromosomal mapping of the TNF-α inducible endothelial protein 1 (Edp1) gene in the mouse. Biochem. Biophys. Acta 1442, 394398.
  • Takakubo F., Yamamoto M., Ogawa N., Yamashita Y., Mizuno Y., Kondo I. (1996) Genetic association between cytochrome P450Ia1 gene and susceptibility to Parkinson's disease. J. Neural. Transm. 103, 843849.
  • Wrighton S. A. & Stevens J. C. (1992) The human cytochromes P450 involved in drug metabolism. Crit. Rev. Toxicol. 22, 121.
  • Youdim M. B., Grunblatt E., Mandel S. (1999) The pivotal role of iron in NF-kappa B activation and nigrostriatal dopaminergic neurodegeneration. Prospects for neuroprotection in Parkinson’s disease with iron chelaters. Ann. NY Acad. Sci. 890, 725.